← Back to Search

Other

Methamphetamine Hydrochloride Tablets for Methamphetamine Addiction (MATAAR Trial)

Phase 4
Waitlist Available
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

MATAAR Trial Summary

This trial looks at how a certain receptor in the brain affects people's addiction to methamphetamine. Two different versions of the receptor will be studied to see how they react differently to the drug.

MATAAR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Brain activation during resting state MRI

MATAAR Trial Design

4Treatment groups
Experimental Treatment
Group I: Wild Type (WT) MUD GroupExperimental Treatment3 Interventions
Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
Group II: Wild Type (WT) Healthy Control GroupExperimental Treatment3 Interventions
Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
Group III: Common Variant (CV) MUD GroupExperimental Treatment3 Interventions
Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
Group IV: Common Variant (CV) Healthy Control GroupExperimental Treatment3 Interventions
Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic resonance imaging (MRI)
2019
Completed Phase 4
~1080
Placebo oral tablet
2019
Completed Phase 4
~2450
Metamfetamine
FDA approved

Find a Location

Who is running the clinical trial?

Portland VA Medical CenterFED
41 Previous Clinical Trials
7,273 Total Patients Enrolled
Oregon Health and Science UniversityLead Sponsor
974 Previous Clinical Trials
7,385,843 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must participants satisfy to take part in this experiment?

"This clinical trial is available to individuals who are between 18 and 55 years old, suffer from methamphetamine dependence, and meet other eligibility requirements. The study will accept a maximum of 200 participants in total."

Answered by AI

What is the cap on enrollment for this trial?

"Indeed, the clinicaltrials.gov database reveals that this research is proactively recruiting participants. It was first listed on August 16th 2019 and updated September 21st 2022; 200 patients at two sites are needed for enrollment."

Answered by AI

Has Methamphetamine Hydrochloride Tablets been tested in any previous research?

"As of now, 5 clinical trials are underway to assess the safety and efficacy of Methamphetamine Hydrochloride Tablets. Of those, none have reached Phase 3 yet. There are 8 trial sites in total located in Chicago, Illinois where patients can participate."

Answered by AI

Does this trial include individuals aged fifty and above?

"According to the trial's requirements, participants must be between 18 and 55 years of age."

Answered by AI

To what degree does Methamphetamine Hydrochloride Tablets pose a risk to individuals?

"Our team at Power gave Methamphetamine Hydrochloride Tablets a score of 3 due to this Phase 4 trial, indicating that the medication has been approved."

Answered by AI

Are new participants being accepted at this time for the clinical trial?

"Confirmed. The information available on clinicaltrials.gov demonstrates that this trial is presently recruiting participants, having first been posted in August 2019 and most recently updated in September 2022. 200 people need to be enrolled from 2 sites for the study to continue."

Answered by AI

Who else is applying?

What state do they live in?
Oregon
How old are they?
18 - 65
What site did they apply to?
Oregon Health and Science University
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I have recently been diagnosed with relatively severe heart failure in the right side of my heart. I also have pulmonary hypertension. According to my doctors this is 100% from doing meth. I won’t get better, even on medication, if I can’t quit. I can barely move without being totally winded. I want to improve my quality of life.
PatientReceived 2+ prior treatments

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Oregon Health and Science University: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
William Hoffman, PhD, MD 2019. "Effects of Genotype on Resting State Connectivity During Methamphetamine Administration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03973489.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top